Glycolysis is an important sugar degradation pathway that cancer cells in particular depend on. Scientists at the German Cancer Research Center (DKFZ) have now shown that liver cancer cells in mice and humans depend on a key enzyme of glycolysis, Aldolase A. When it is switched off, glycolysis reverses from an energy-producing to an energy-consuming process.

Young patients suffering from two aggressive sarcoma types can now participate in the innovative PAMSARC therapy study at the NCT Heidelberg. The study uses molecular biological methods and tests the extent to which a new drug can improve the poor prognosis for these tumours.

Winfried Kretschmann, the Minister President of Baden-Württemberg, Germany, visited the Max Planck Institutes for Biology Tübingen and Biological Cybernetics. During his tour, he commended the outstanding basic research in the natural sciences. He was particularly impressed by the innovative research projects spanning developmental and evolutionary biology, as well as neuroscience.

Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging and re-emerging viruses.

University of Tübingen research team observes biochemical process in living cells – indications of new approach to preventing heart attacks and strokes